Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation

Blood

Volumn 114, Issue 8, 2009, Pages 1658-1665

  Ni Ainle, Fionnuala ^a   Preston, Roger J S ^a   Jenkins, P Vincent ^a   Nel, Hendrik J ^a   Johnson, Jennifer A ^a   Smith, Owen P ^b   White, Barry ^a   Fallon, Padraic G ^a   O'Donnell, James S ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; DANAPAROID; ENOXAPARIN; HEPARIN; PROTAMINE SULFATE; THROMBIN; THROMBOPLASTIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 8A; PROTAMINE; PROTEIN C;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; HUMAN; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTHROMBIN TIME; ANIMAL; BAGG ALBINO MOUSE; BLOOD CLOTTING; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; METABOLISM; PHYSIOLOGY; PROTEIN PROCESSING;

ANIMALS; ANTICOAGULANTS; BLEEDING TIME; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FACTOR V; FACTOR VIIIA; HEPARIN; MICE; MICE, INBRED BALB C; PROTAMINES; PROTEIN C; PROTEIN PROCESSING, POST-TRANSLATIONAL; THROMBIN;

EID: 70349581807     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-222109     Document Type: Article

References (37)

1. Horrow JC. Protamine: a review of its toxicity. Anesth Analg. 1985;64:348-361.
2. Carr JA, Silverman N. The heparin-protamine interaction: a review. J Cardiovasc Surg. 1999;40: 659-666.
3. Baglin T, Barrowcliffe TW, Cohen A, Greaves M. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006;133:19-34.
4. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(suppl 6):141S-159S.
5. Dunning J, Versteegh M, Fabbri A, et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008;34:73-92.
6. Brecher AS, Roland AR. Protamine inhibits formation of the covalent factor IXa-anti-thrombin complex. Blood Coagul Fibrinolysis. 2008;19: 591-596.
7. ChuAJ,Wang ZG, Raicu M, Beydoun S, Ramos N. Protamine inhibits tissue factor-initiated extrinsic coagulation. Br J Haematol. 2001;115:392-399. (Pubitemid 34203508)
8. Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781-785.
9. McLaughlin KE, Dunning J. In patients post-cardiac surgery, do high doses of protamine cause increased bleeding? Interact Cardiovasc Thorac Surg. 2003;2:424-426. (Pubitemid 38112776)
10. Butterworth J, Lin YA, Prielipp RC, Bennett J, Hammon JW, James RL. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg. 2002;74:1589-1595. (Pubitemid 35222646)
11. Butterworth J, Lin YA, Prielipp R, Bennett J, James R. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg. 2002; 94:514-522. (Pubitemid 34177542)
12. Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost. 1990;63:271-274. (Pubitemid 20128194)
13. Wolzt M, Weltermann A, Nieszpaur-Los M, et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost. 1995;73:439-443.
14. Perkash A. A comparison of the quantitative action of protamine and heparin on blood coagulation: significance in clinical and laboratory usage. Am J Clin Pathol. 1980;73:676-681. (Pubitemid 10047201)
15. Nielsen VG. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg. 2006;81:1720-1727.
16. Preston RJ, Tran S, Johnson JA, et al. Platelet factor 4 impairs the anticoagulant activity of activated protein C. J Biol Chem. 2009;284:5869-5875.
17. Harmon S, Preston RJ, Ainle FN, et al. Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J Biol Chem. 2008;283:30531-30539.
18. Varfaj F, Wakabayashi H, Fay PJ. Residues surrounding Arg336 and Arg562 contribute to the disparate rates of proteolysis of factor VIIIa catalyzed by activated protein C. J Biol Chem. 2007; 282:20264-20272. (Pubitemid 47100001)
19. Safa O, Morrissey JH, Esmon CT, Esmon NL. Factor VIIa/tissue factor generates a form of factor V with unchanged specific activity, resistance to activation by thrombin, and increased sensitivity to activated protein C. Biochemistry. 1999;38: 1829-1837. (Pubitemid 129507243)
20. Mittermayr M, Velik-Salchner C, Stalzer B, et al. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study. Anesth Analg. 2009;108:743-750.
21. Kresowik TF, Wakefield TW, Fessler RD, Stanley JC. Anticoagulant effects of protamine sulfate in a canine model. J Surg Res. 1988;45:8-14.
22. Merskey C. Defibrination syndrome or? Blood. 1973;41:599-603.
23. Orfeo T, Brufatto N, Nesheim ME, Xu H, Butenas S, Mann KG. The factor V activation paradox. J Biol Chem. 2004;279:19580-19591.
24. Cobel-Geard RJ, Hassouna HI. Interaction of protamine sulfate with thrombin. Am J Hematol. 1983;14;227-233.
25. Miyashita T, Nakajima T, Hayashi Y, Kuro M. Hemostatic effects of low-dose protamine following cardiopulmonary bypass. Am J Hematol. 2000; 64:112-115. (Pubitemid 30324468)
26. Griffin MJ, Rinder HM, Smith BR, et al. The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress. Anesth Analg. 2001; 93:20-27.
27. DeLaria GA, Tyner JJ, Hayes CL, Armstrong BW. Heparin-protamine mismatch: a controllable factor in bleeding after open heart surgery. Arch Surg. 1994;129:944-950.
28. Despotis GJ, Joist JH, Hogue CW Jr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46-54.
29. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg. 1995;110:36-45.
30. Verska JJ. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis. Ann Thorac Surg. 1977;24: 170-173.
31. Mann KG, Kalafatis M. Factor V: a combination of Dr. Jekyll and Mr. Hyde. Blood. 2003;101:20-30.
32. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem. 1979;254: 10952-10962.
33. Mast AE, Broze GJ Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. Blood. 1996;87:1845-1850.
34. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A. 2006;103:903-908. (Pubitemid 43212194)
35. Smith SA, Morrissey JH. Heparin is procoagulant in the absence of antithrombin. Thromb Haemost. 2008;100:160-162.
36. Liu T, Scallan CD, Broze GJ Jr, Patarroyo-White S, Pierce GF, Johnson KW. Improved coagulation in bleeding disorders by non-anticoagulant sulfated polysaccharides (NASP). Thromb Haemost. 2006;95:68-76.
37. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood. 2008;112: 2810-2816.